Ubs Group Ag Tango Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 277,102 shares of TNGX stock, worth $1.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

277,102

Previous 153,335 80.72%

Holding current value

$1.91 Million

Previous $210,000 575.24%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.1 - $5.47 $136,143 - $677,005	123,767 Added 80.72%	277,102 $1.42 Million
Q1 2025 May 13, 2025	SELL	$1.37 - $3.47 $357,759 - $906,148	-261,138 Reduced 63.0%	153,335 $210,000
Q4 2024 Feb 14, 2025	SELL	$2.79 - $7.46 $73,538 - $196,630	-26,358 Reduced 5.98%	414,473 $1.28 Million
Q3 2024 Nov 14, 2024	BUY	$7.36 - $11.93 $2.13 Million - $3.45 Million	289,516 Added 191.33%	440,831 $3.39 Million
Q2 2024 Aug 13, 2024	SELL	$6.66 - $10.15 $46,027 - $70,146	-6,911 Reduced 4.37%	151,315 $1.3 Million
Q1 2024 May 13, 2024	BUY	$7.51 - $12.88 $1.19 Million - $2.04 Million	158,226 New	158,226 $1.26 Million
Q3 2023 Nov 09, 2023	SELL	$2.93 - $11.26 $430 - $1,655	-147 Reduced 0.47%	30,988 $348,000
Q2 2023 Aug 11, 2023	BUY	$2.67 - $4.7 $28,416 - $50,022	10,643 Added 51.94%	31,135 $103,000
Q1 2023 May 12, 2023	BUY	$3.76 - $8.06 $15,156 - $32,489	4,031 Added 24.49%	20,492 $80,000
Q4 2022 Feb 08, 2023	BUY	$3.41 - $8.29 $56,132 - $136,461	16,461 New	16,461 $119,000
Q2 2022 Aug 10, 2022	BUY	$3.86 - $8.01 $66,295 - $137,571	17,175 Added 837.8%	19,225 $87,000
Q1 2022 May 16, 2022	SELL	$7.01 - $10.94 $3,743 - $5,841	-534 Reduced 20.67%	2,050 $16,000
Q4 2021 Feb 14, 2022	BUY	$9.55 - $14.29 $24,677 - $36,925	2,584 New	2,584 $28,000

Others Institutions Holding TNGX

# of Institutions

123

Shares Held

117M

Call Options Held

245K

Put Options Held

18.9K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $609M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account